Salman Khan1, Rudi Fnu Safarudin2, Justin T Kupec3. 1. Department of Medicine, School of Medicine, West Virginia University, USA. Electronic address: salman.khan@hsc.wvu.edu. 2. Department of Pharmaceutical Systems and Policy, West Virginia University School of Pharmacy, USA; School of Mathematics and Natural Sciences, Tadulako University, Indonesia. 3. Section of Gastroenterology & Hepatology, West Virginia University, Morgantown, West Virginia, USA.
Abstract
BACKGROUND: Patients with new-onset diabetes are known to be at a higher risk of developing pancreatic cancer. The Enriching New-Onset Diabetes for Pancreatic Cancer (ENDPAC) model was recently developed to identify new-onset diabetics with this higher risk. Further validation is needed before the ENDPAC model is implemented as part of a screening program to identify pancreatic cancer. METHODS: A retrospective case-control study was performed; a cohort of patients with new-onset diabetes was identified using hemoglobin A1c. Patients were scored by the ENDPAC model and then divided based on whether pancreatic cancer was diagnosed after the diagnosis of diabetes. The performance of the model was assessed globally and at different cutoffs. RESULTS: There were 6254 controls and 48 cases of pancreatic cancer. Bivariate analysis showed that patients with pancreatic cancer lost weight before diagnosis while controls gained weight (-0.93 kg/m2 vs. 0.45 kg/m2, p < 0.00∗). Cases had a more significant increase in their HbA1C from one year before (1.3% vs. 0.82%, p = 0.02). Smoking and pancreatitis rates were higher in cases compared to controls (p < 0.00∗). The area under the curve (AUC) of the ENDPAC model was 0.72. A score >1 was the optimal cutoff. At this cutoff, the sensitivity was 56%, specificity was 75%, and pancreatic cancer prevalence increased from 0.78% at baseline to 1.7%. CONCLUSION: The ENDPAC model was validated in an independent cohort of patients with new-onset diabetes.
BACKGROUND: Patients with new-onset diabetes are known to be at a higher risk of developing pancreatic cancer. The Enriching New-Onset Diabetes for Pancreatic Cancer (ENDPAC) model was recently developed to identify new-onset diabetics with this higher risk. Further validation is needed before the ENDPAC model is implemented as part of a screening program to identify pancreatic cancer. METHODS: A retrospective case-control study was performed; a cohort of patients with new-onset diabetes was identified using hemoglobin A1c. Patients were scored by the ENDPAC model and then divided based on whether pancreatic cancer was diagnosed after the diagnosis of diabetes. The performance of the model was assessed globally and at different cutoffs. RESULTS: There were 6254 controls and 48 cases of pancreatic cancer. Bivariate analysis showed that patients with pancreatic cancer lost weight before diagnosis while controls gained weight (-0.93 kg/m2 vs. 0.45 kg/m2, p < 0.00∗). Cases had a more significant increase in their HbA1C from one year before (1.3% vs. 0.82%, p = 0.02). Smoking and pancreatitis rates were higher in cases compared to controls (p < 0.00∗). The area under the curve (AUC) of the ENDPAC model was 0.72. A score >1 was the optimal cutoff. At this cutoff, the sensitivity was 56%, specificity was 75%, and pancreatic cancer prevalence increased from 0.78% at baseline to 1.7%. CONCLUSION: The ENDPAC model was validated in an independent cohort of patients with new-onset diabetes.
Authors: Suresh T Chari; Cynthia L Leibson; Kari G Rabe; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen Journal: Gastroenterology Date: 2005-08 Impact factor: 22.682
Authors: Guido Eibl; Zobeida Cruz-Monserrate; Murray Korc; Maxim S Petrov; Mark O Goodarzi; William E Fisher; Aida Habtezion; Aurelia Lugea; Stephen J Pandol; Phil A Hart; Dana K Andersen Journal: J Acad Nutr Diet Date: 2017-09-12 Impact factor: 4.910
Authors: Suresh T Chari; Cynthia L Leibson; Kari G Rabe; Lawrence J Timmons; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen Journal: Gastroenterology Date: 2007-10-26 Impact factor: 22.682
Authors: Dana K Andersen; Murray Korc; Gloria M Petersen; Guido Eibl; Donghui Li; Michael R Rickels; Suresh T Chari; James L Abbruzzese Journal: Diabetes Date: 2017-05 Impact factor: 9.461
Authors: Suresh T Chari; Anirban Maitra; Lynn M Matrisian; Eva E Shrader; Bechien U Wu; Avinash Kambadakone; Ying-Qi Zhao; Barbara Kenner; Jo Ann S Rinaudo; Sudhir Srivastava; Ying Huang; Ziding Feng Journal: Contemp Clin Trials Date: 2021-12-23 Impact factor: 2.226
Authors: Agnieszka Lemanska; Claire A Price; Nathan Jeffreys; Rachel Byford; Hajira Dambha-Miller; Xuejuan Fan; William Hinton; Sophie Otter; Rebecca Rice; Ali Stunt; Martin B Whyte; Sara Faithfull; Simon de Lusignan Journal: PLoS One Date: 2022-10-05 Impact factor: 3.752
Authors: Bechien U Wu; Eva Lustigova; Qiaoling Chen; Elizabeth Y Dong; Anirban Maitra; Suresh T Chari; Ziding Feng; Jo Ann Rinaudo; Lynn M Matrisian; Rex A Parker Journal: Clin Transl Gastroenterol Date: 2022-06-01 Impact factor: 4.396